uniQure Outlines Key Initiatives for 2017 and Vision for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
40
uniQure Outlines Key Initiatives for 2017 and Vision for 2018

-- Preparations Underway for Late-Stage Development in Hemophilia B

-- Three Clinical-Stage Programs by 2018 Including One Pivotal and Two Proof-of-Concept Studies

-- Company Strengthened Following Strategic Review and New Executive Leadership

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 09, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE ), a leader in human gene therapy, today announced its key corporate initiatives for 2017 and vision for 2018 following the completion of a company-wide strategic review late last year that refocuses its pipeline, streamlines operations, improves its financial position and enhances overall execution and shareholder value.  uniQure management is meeting with investors and analysts this week in conjunction with the 35 th Annual J.P. Morgan Healthcare Conference taking place in San Francisco. An updated corporate presentation is posted to the investor page of the Company’s website, www.uniqure.com . 

“As we begin 2017, we expect each of our core programs to achieve important milestones that will bring us closer to delivering life-transforming gene therapies for patients,” stated Matthew Kapusta, chief executive officer of uniQure.  “Our key focus is to rapidly advance our hemophilia B program into late-stage development.  By 2018, we expect to have three clinical-stage programs, including a pivotal study for AMT-060 in hemophilia B, and two clinical proof-of-concept studies for congestive heart failure and Huntington’s disease.  We believe our financial position is strong and capable of funding the accomplishment of these objectives.” 

Recent Accomplishments

  • Hemophilia B – Presented positive new and updated clinical data on AMT-060 at the 58 th American Society of Hemophilia (ASH) Annual Meeting demonstrating clinically significant and sustained increases in FIX activity, substantial reductions in FIX replacement usage and a near cessation of spontaneous bleeding in patients with severe disease at up to 12 months follow-up.   
  • Huntington’s disease – Published in a peer-reviewed journal preclinical data showing sustained and strong wild-type HTT protein silencing in humanized control mice, including knock-down efficiency up to 80% using optimized miHTT scaffolds.     
  • Collaboration with Bristol-Myers Squibb (BMS) – Made significant progress in transferring S100A1 to uniQure’s proprietary insect-cell, baculovirus platform, as well as conducting preclinical dose-ranging analyses and comparability studies.  
  • Strategic review – Announced the completion of a company-wide strategic review to refocus its pipeline, streamline operations, reduce operating costs and enhance execution and long-term shareholder value.  
  • Leadership – Appointed Matthew Kapusta as Chief Executive Officer in December 2016.

Key Corporate Initiatives for 2017

  • Advance hemophilia B program towards late-stage clinical development – The Company intends to initiate a pivotal trial for AMT-060 in hemophilia B pending discussions with regulatory authorities that are expected to take place in early 2017.   
  • Advance AMT-130 in Huntington’s disease program towards IND filing – The Company plans to file an investigational new drug (IND) application for Huntington’s disease following the completion of ongoing IND-enabling studies, including the initiation of additional safety and toxicology studies.    
  • Advance AMT-120 in heart failure towards IND filing – uniQure’s collaboration with BMS in cardiovascular diseases is a top research priority, specifically focused on the advancement of S100A1 in congestive heart failure.  The Company expects to initiate preclinical functional and safety studies for S100A1 in 2017, as well as conduct additional research activities for two additional product candidates designated by BMS.  
  • Presentation of preclinical and clinical data – Data presentations on programs in hemophilia B and Huntington’s disease are expected in 2017, including longer-term safety and efficacy data on AMT-060 from the ongoing Phase I/II clinical trial and preclinical data on AMT-130 in Huntington’s disease.
  • Initiate manufacturing campaigns – uniQure expects to initiate cGMP manufacturing campaigns for all anticipated clinical programs in its Lexington, MA facility in 2017.  The Lexington facility is fully operational and has the capability of scaling up to 2,000L capacity, which uniquely positions the Company for late-stage development and commercialization of its gene therapy products, importantly AMT-060.

uniQure had approximately €140 million ($158 million) in cash and cash equivalents as of September 30, 2016, which is expected to fund operations into 2019.

About uniQure uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com .

uniQure Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the implementation and effects of the Company’s new strategic and organizational changes, the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with corporate reorganizations and strategic shifts, collaboration arrangements, our and our collaborators’ clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 m.cantor@uniQure.com Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 t.malone@uniQure.com Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 e.mulder@uniQure.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 117

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 162

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 29

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 90

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 132

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 101

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 138

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 66

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 208

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading

Top 5 Most Recently Viewed Articles

Alliance Entertainment Expands Leadership with Robert Oram

Updated Category News Views 137

Alliance Entertainment Welcomes Robert Oram as EVP Alliance Entertainment Holding Corporation (NASDAQ: AENT) has made a significant addition to its leadership team with the appointment of Robert Oram as the Executive Vice President. This strategic move, announced recently, aims to bolster the company's efforts in expanding its home entertainment division. Oram, a veteran...

Continue Reading
Teradyne Inc: Navigating AI Growth in Semiconductor Testing

Updated Category News Views 155

Teradyne Inc (NASDAQ: TER) was one of those stocks that had traders buzzing back in 2023 when it saw gains up to 50% early in the year. That kind of momentum, especially outpacing the Philadelphia Semiconductor Index, had folks dreaming big. But reality hit later on as the market pulled back, reminding everyone that nothing lasts forever in this volatile game. Market...

Continue Reading
Transforming Landscapers' Cash Flow with Duranta's Payments

Updated Category News Views 163

Duranta Unveils a Game-Changer for Landscapers' Payments Duranta, the AI-driven platform for landscaping professionals, is set to reshape how landscaping businesses handle payments. Recently, they introduced an innovative feature that embeds secure payment links directly into customer invoices. This new function streamlines transaction methods for landscapers, making it...

Continue Reading
Analyzing Market Trends: The Case of WR Berkley Stock

Updated Category News Views 146

Understanding WR Berkley and Its Market Position WR Berkley Corporation (NYSE: WRB) has been making headlines recently due to its fluctuating short interest levels. The company, known for its diverse insurance offerings, recorded a significant rise in its short percent of float, now standing at 22.48%. This figure comes from its recent announcement that approximately 7.96...

Continue Reading
Timbercreek Financial to Host Q4 Results Call - Key Details Inside

Updated Category News Views 153

Timbercreek Financial's Upcoming Conference Call Timbercreek Financial (TSX: TF) is gearing up for an important conference call to discuss its financial results for the last quarter. This call is set for 1:00 p.m. (ET) on a Wednesday. The insights into the company’s performance will be revealed shortly after the markets close. Stakeholders and interested parties are...

Continue Reading